iHealthScreen Inc. Announces CE Certification for iPredict ™ Automated AI System for Early Diagnosis of Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD), and Glaucoma Suspect
iPredict™ AI Eye Screening System provides fully automated diabetic retinopathy (DR), age related macular degeneration (AMD), and glaucoma suspect screening, including retinal imaging, and immediate reporting of actionable results. Using the iPredict™ System,primary care and various specialty practices can accurately and efficiently screen diabetic patients for DR, people over 50 for AMD, and those with a family history of glaucoma or other risk factors for suspected glaucoma.
Once high-resolution images of the patient’s eyes have been captured using a color fundus camera and submitted to the iPredict™ AI System, the screening results are available in a fully automated report in less than 60 seconds. The entire test can easily and reliably be completed within 5 minutes.
iPredict’s CE certification indications for use as follows:
- iPredict-DR can detect more than mild DR or vision threatening DR such as severe non-Proliferative DR, proliferative and diabetic macular EDEMA.
- iPredict-AMD can detect referable AMD such as intermediate to late AMD and non-referable AMD such as early or none.
- iPredict-glaucoma detects glaucoma suspects based on abnormal optic discs.
If referable stage disease is detected for any of these conditions, the iPredict automated report recommends a visit to an Ophthalmologist for appropriate treatment. Otherwise, in accordance with standards of care, a follow up visit in one year is suggested.
iPredict is indicated for use by healthcare providers in clinics, hospitals or other healthcare facilities to automatically detect DR, AMD and glaucoma suspect.
“This technology could be particularly useful in identifying someone who has slipped across the boundary to progress into severity,” Dr. Theodore Smith (Professor in Ophthalmology and Neuroscience at Icahn School of Medicine at Mount Sinai, New York) said.
“This is a major milestone for iHealthScreen. iPredict™ eye disease diagnostic tools will help prevent blindness for millions of people and save insurers countless millions of dollars in avoidable healthcare cost,” said Dr. Alauddin Bhuiyan, the founder and CEO of the company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Alauddin Bhuiyan, Ph.D.
CEO, iHealthScreen Inc.
T: +1 718 926 9000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. WhiteHorse Provides Financing to Avalon20.9.2021 12:54:00 CEST | Press release
H.I.G. WhiteHorse, a credit affiliate of global investment firm H.I.G. Capital ("H.I.G.") is pleased to announce that it has arranged a £55 million unitranche financing package for AnaCap Financial Partners (“AnaCap”) in support of its sector growth and consolidation strategy in the UK wealth management platform industry. To date, AnaCap, a leading specialist European financial services private equity firm, has completed three platform acquisitions as part of its buy and build strategy: Wealthtime, Amber Financial Investments (“Amber”), and Novia Financial (“Novia”), together “Avalon” or the “Combined Group.” Across the three investments, AnaCap has now acquired almost £11.0 billion AuA and will continue to deploy its expertise in tech-enabled businesses and operational engagement to bolster the business’ organic expansion and identify attractive bolt-on acquisition opportunities. Eric Verret, Head of Capital Markets at AnaCap, said: “Being able to secure financing through H.I.G. White
The Climate Pledge Announces 86 New Signatories, Including Procter & Gamble, HP, and Salesforce, Signaling Their Commitment to Achieving Net-Zero Carbon by 2040 or Sooner20.9.2021 12:00:00 CEST | Press release
Today, Amazon and Global Optimism announced that more than 200 companieshave now signed The Climate Pledge. The 86 new signatories joining The Climate Pledge include Procter & Gamble, HP, Salesforce, ASOS, and Nespresso. Pledge signatories in total generate over $1.8 trillion in global annual revenues and have more than 7 million employees across 26 industries in 21 countries. By achieving net-zero carbon by 2040, 10 years ahead of the Paris Agreement, current Climate Pledge signatories are expected to collectively mitigate 1.98 billion metric tons (BMT) of carbon emissions from a 2020 baseline. This is equivalent to 5.4% of current global annual emissions—demonstrating the collective impact The Climate Pledge is expected to have in addressing climate change and prompting more action to tackle the climate crisis. Signatories to The Climate Pledge agree to: Measure and report greenhouse gas emissions on a regular basis. Implement decarbonization strategies in line with the Paris Agreeme
AlbaCore Capital Group Continues to Expand with Three Senior Hires20.9.2021 11:20:00 CEST | Press release
European credit specialist AlbaCore Capital Group (“AlbaCore”), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams. As part of the growth of the AlbaCore platform, investing across the European credit spectrum with $8.5bn1 AUM, AlbaCore has bolstered its senior executive group. Jenny Fung is appointed as Managing Director of Investor Relations in New York to further expand global investor relationships and our commitment to the region. Tara Mulholland joins as Head of Business Transformation and Micaela Kelley as Deputy Chief Operating Officer to support Matthew Courey, Chief Operating Officer and Founding Partner. Jenny brings a wealth of financial services experience with 25 years in the industry. She joins from Taconic Capital, a global investment firm, where she was Director of Marketing and Investor Relations for 13 years, and prior to that at Bank of America, AIG and CSFB. Tara will oversee an operational change progr
Cedo Reveals Roadmap for Sustainable Business Growth20.9.2021 09:00:00 CEST | Press release
Cedo, one of Europe’s largest manufacturers of recycled plastic waste bags has today revealed its Roadmap for Sustainable Business Growth. The plan is built on three pillars: People, Planet and Products and comes with targets designed to protect the earth’s resources while attracting and nurturing talent within the business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005048/en/ Cedo CEO, Rik De Vos, says “Cedo is proud of our contribution to achieving the goals of sustainable business development outlined by the UN” (Photo: Business Wire) “Our plan has been built with deep engagement from all the employees within our company,” says Rik De Vos, CEO of Cedo. “The journey to circularity will not be easy, but I have seen an immediate shift in decision making, and prioritisation of actions now that we are a purpose-led business. We are actively contributing to European and UK legislative debate to accelerate this transf
Coffee Pod Convenience Without the Landfill Guilt: Introducing the Home-Compostable Coffee Capsule, Co-Developed by Jabil and Prosol20.9.2021 08:00:00 CEST | Press release
Jabil Packaging Solutions (JPS), a division of manufacturing solutions provider Jabil Inc. (NYSE: JBL), today announced a significant advancement in coffee pod sustainability with the launch of their home-compostable coffee capsule for single serve espresso brewers. This high-barrier coffee capsule improves on existing solutions by eliminating the need for a plastic or foil pouch that is sometimes required to preserve freshness in compostable coffee capsules. JPS co-developed the compostable coffee capsule with Productos Solubles S.A. (Prosol), a leading European coffee roaster, based in Palencia, Spain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210919005012/en/ Co-developed by Jabil Packaging Solutions and Productos Solubles S.A. (Prosol), the home-compostable coffee capsule improves on existing solutions and is a significant advancement in coffee pod sustainability. (Photo: Business Wire) The technically complex coffe
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w
Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom